Quick Answer
Tango Therapeutics, Inc. reported Research And Development Expense of $132.17 million for the year ending 2025.
- Tango Therapeutics, Inc. showed a decrease of -8.2% in Research And Development Expense from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Research And Development Expense has grown by 164.4%.
- Historical annual values: Fiscal year 2025: $132.17 million | Fiscal year 2024: $143.92 million | Fiscal year 2023: $115.20 million | Fiscal year 2022: $105.91 million | Fiscal year 2021: $77.64 million | Fiscal year 2020: $49.99 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: